

US009339592B2

(12) **United States Patent**
Pacetti

(10) **Patent No.:** **US 9,339,592 B2**
(45) **Date of Patent:** ***May 17, 2016**

(54) **POLYMERS OF FLUORINATED MONOMERS AND HYDROCARBON MONOMERS**

(75) Inventor: **Stephen D. Pacetti**, San Jose, CA (US)

(73) Assignee: **Abbott Cardiovascular Systems Inc.**, Santa Clara, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1253 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **11/784,997**

(22) Filed: **Apr. 9, 2007**

(65) **Prior Publication Data**

US 2007/0191561 A1 Aug. 16, 2007

Related U.S. Application Data

(62) Division of application No. 11/021,775, filed on Dec. 22, 2004.

(51) **Int. Cl.**

C08L 27/12 (2006.01)
C08L 23/04 (2006.01)
A61L 31/04 (2006.01)
A61L 31/10 (2006.01)
A61L 31/16 (2006.01)
C08F 214/18 (2006.01)
C08F 295/00 (2006.01)
C09D 127/16 (2006.01)
A61K 31/436 (2006.01)

(52) **U.S. Cl.**

CPC **A61L 31/048** (2013.01); **A61K 31/436** (2013.01); **A61L 31/10** (2013.01); **A61L 31/16** (2013.01); **C08F 214/18** (2013.01); **C08F 295/00** (2013.01); **C09D 127/16** (2013.01); **A61L 2300/416** (2013.01)

(58) **Field of Classification Search**

USPC 525/191; 424/423; 524/520, 544; 604/265

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,072,303 A 3/1937 Herrmann et al.
2,386,454 A 10/1945 Frosch et al.
3,773,737 A 11/1973 Goodman et al.
3,849,514 A 11/1974 Gray, Jr. et al.
4,226,243 A 10/1980 Shalaby et al.
4,329,383 A 5/1982 Joh
4,343,931 A 8/1982 Barrows
4,529,792 A 7/1985 Barrows
4,611,051 A 9/1986 Hayes et al.
4,656,242 A 4/1987 Swan et al.
4,733,665 A 3/1988 Palmaz
4,800,882 A 1/1989 Gianturco
4,882,168 A 11/1989 Casey et al.
4,886,062 A 12/1989 Wiktor
4,931,287 A 6/1990 Bae et al.
4,941,870 A 7/1990 Okada et al.

4,977,901 A 12/1990 Ofstead
5,019,096 A 5/1991 Fox, Jr. et al.
5,037,914 A 8/1991 Monti et al.
5,100,992 A 3/1992 Cohn et al.
5,112,457 A 5/1992 Marchant
5,133,742 A 7/1992 Pinchuk
5,163,952 A 11/1992 Froix
5,165,919 A 11/1992 Sasaki et al.
5,219,980 A 6/1993 Swidler
5,258,020 A 11/1993 Froix
5,272,012 A 12/1993 Opolski
5,284,184 A 2/1994 Noone et al.
5,286,822 A 2/1994 Krespan et al.
5,292,516 A 3/1994 Viegas et al.
5,298,260 A 3/1994 Viegas et al.
5,300,295 A 4/1994 Viegas et al.
5,306,501 A 4/1994 Viegas et al.
5,306,786 A 4/1994 Moens et al.
5,328,471 A 7/1994 Slepian
5,330,768 A 7/1994 Park et al.
5,380,299 A 1/1995 Fearnot et al.
5,417,981 A 5/1995 Endo et al.
5,447,724 A 9/1995 Helmus et al.
5,455,040 A 10/1995 Marchant
5,462,990 A 10/1995 Hubbell et al.
5,464,650 A 11/1995 Berg et al.
5,485,496 A 1/1996 Lee et al.
5,516,881 A 5/1996 Lee et al.
5,569,463 A 10/1996 Helmus et al.
5,578,073 A 11/1996 Haimovich et al.
5,584,877 A 12/1996 Miyake et al.
5,605,696 A 2/1997 Eury et al.
5,607,467 A 3/1997 Froix
5,609,629 A 3/1997 Fearnot et al.
5,610,241 A 3/1997 Lee et al.
5,616,338 A 4/1997 Fox, Jr. et al.
5,624,411 A 4/1997 Tuch
5,628,730 A 5/1997 Shapland et al.

(Continued)

FOREIGN PATENT DOCUMENTS

DE 42 24 401 1/1994
EP 0 161 804 4/1985

(Continued)

OTHER PUBLICATIONS

Zhang et al., "Synthesis of fluorine-containing block copolymers via ATRP 1. Synthesis and characterization of PSt-PVDF-PSt triblock copolymers", Polymer, vol. 40, pp. 1341-1345 (1999).*

(Continued)

Primary Examiner — Peter D Mulcahy

Assistant Examiner — Henry Hu

(74) *Attorney, Agent, or Firm* — Squire Patton Boggs (US) LLP

(57) **ABSTRACT**

A polymer of fluorinated monomers and hydrocarbon monomers is provided. It is also provided a polymer blend that contains a polymer-formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer. The polymer or polymer blend described herein and optionally a bioactive agent can form an implantable device such as a stent or a coating on an implantable device such as a drug-delivery stent, which can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

5 Claims, No Drawings

(56)

References Cited

U.S. PATENT DOCUMENTS

5,628,786 A *	5/1997	Banas et al. 623/1.13	6,120,788 A	9/2000	Barrows
5,644,020 A	7/1997	Timmermann et al.	6,120,904 A	9/2000	Hostettler et al.
5,649,977 A	7/1997	Campbell	6,121,027 A	9/2000	Clapper et al.
5,658,995 A	8/1997	Kohn et al.	6,124,386 A *	9/2000	Yokota et al. 524/154
5,667,767 A	9/1997	Greff et al.	6,129,761 A	10/2000	Hubbell
5,670,558 A	9/1997	Onishi et al.	6,136,333 A	10/2000	Cohn et al.
5,674,242 A	10/1997	Phan et al.	6,143,354 A	11/2000	Koulik et al.
5,679,400 A	10/1997	Tuch	6,153,252 A	11/2000	Hossainy et al.
5,700,286 A	12/1997	Tartaglia et al.	6,159,978 A	12/2000	Myers et al.
5,702,754 A	12/1997	Zhong	6,165,212 A	12/2000	Dereume et al.
5,711,958 A	1/1998	Cohn et al.	6,168,619 B1 *	1/2001	Dinh et al. 623/1.13
5,716,981 A	2/1998	Hunter et al.	6,172,167 B1	1/2001	Stapert et al.
5,721,131 A	2/1998	Rudolph et al.	6,177,523 B1	1/2001	Reich et al.
5,723,219 A	3/1998	Kolluri et al.	6,179,817 B1	1/2001	Zhong
5,735,897 A	4/1998	Buirge	6,180,632 B1	1/2001	Myers et al.
5,746,998 A	5/1998	Torchilin et al.	6,197,051 B1	3/2001	Zhong
5,759,205 A	6/1998	Valentini	6,203,551 B1	3/2001	Wu
5,776,184 A	7/1998	Tuch	6,211,249 B1	4/2001	Cohn et al.
5,783,657 A	7/1998	Pavlin et al.	6,214,901 B1	4/2001	Chudzik et al.
5,788,979 A	8/1998	Alt et al.	6,231,590 B1	5/2001	Slaikou et al.
5,800,392 A	9/1998	Racchini	6,231,600 B1	5/2001	Zhong
5,820,917 A	10/1998	Tuch	6,240,616 B1	6/2001	Yan
5,821,343 A *	10/1998	Keogh 530/402	6,245,753 B1	6/2001	Byun et al.
5,824,048 A	10/1998	Tuch	6,245,760 B1	6/2001	He et al.
5,824,049 A	10/1998	Ragheb et al.	6,248,129 B1	6/2001	Froix
5,830,178 A	11/1998	Jones et al.	6,251,136 B1	6/2001	Guruwaiya et al.
5,837,008 A	11/1998	Berg et al.	6,254,632 B1	7/2001	Wu et al.
5,837,313 A	11/1998	Ding et al.	6,258,121 B1	7/2001	Yang et al.
5,849,859 A	12/1998	Acemoglu	6,258,371 B1	7/2001	Koulik et al.
5,851,508 A	12/1998	Greff et al.	6,262,034 B1	7/2001	Mathiowitz et al.
5,854,376 A	12/1998	Higashi	6,270,788 B1	8/2001	Koulik et al.
5,857,998 A	1/1999	Barry	6,277,449 B1	8/2001	Kolluri et al.
5,858,746 A	1/1999	Hubbell et al.	6,283,947 B1	9/2001	Mirzaee
5,863,612 A	1/1999	Desimone et al.	6,283,949 B1	9/2001	Roorda
5,865,814 A	2/1999	Tuch	6,284,305 B1	9/2001	Ding et al.
5,869,127 A	2/1999	Zhong	6,287,628 B1	9/2001	Hossainy et al.
5,873,904 A	2/1999	Ragheb et al.	6,299,604 B1	10/2001	Ragheb et al.
5,876,433 A	3/1999	Lunn	6,306,176 B1	10/2001	Whitbourne
5,877,224 A	3/1999	Brocchini et al.	6,331,313 B1	12/2001	Wong et al.
5,879,713 A	3/1999	Roth et al.	6,335,029 B1	1/2002	Kamath et al.
5,902,875 A	5/1999	Roby et al.	6,344,035 B1	2/2002	Chudzik et al.
5,905,168 A	5/1999	Dos Santos et al.	6,346,110 B2	2/2002	Wu
5,910,564 A	6/1999	Gruning et al.	6,358,556 B1	3/2002	Ding et al.
5,914,387 A	6/1999	Roby et al.	6,379,381 B1	4/2002	Hossainy et al.
5,919,893 A	7/1999	Roby et al.	6,387,379 B1	5/2002	Goldberg et al.
5,925,720 A	7/1999	Kataoka et al.	6,395,326 B1	5/2002	Castro et al.
5,932,299 A	8/1999	Katoot	6,419,692 B1	7/2002	Yang et al.
5,955,509 A	9/1999	Webber et al.	6,451,373 B1	9/2002	Hossainy et al.
5,958,385 A	9/1999	Tondeur et al.	6,482,834 B2	11/2002	Spada et al.
5,962,138 A	10/1999	Kolluri et al.	6,494,862 B1	12/2002	Ray et al.
5,971,954 A	10/1999	Conway et al.	6,503,538 B1	1/2003	Chu et al.
5,980,928 A	11/1999	Terry	6,503,556 B2	1/2003	Harish et al.
5,980,972 A	11/1999	Ding	6,503,954 B1	1/2003	Bhat et al.
5,997,517 A	12/1999	Whitbourne	6,506,437 B1	1/2003	Harish et al.
6,010,530 A	1/2000	Goicoechea	6,524,347 B1	2/2003	Myers et al.
6,011,125 A	1/2000	Lohmeijer et al.	6,527,801 B1	3/2003	Dutta
6,015,541 A	1/2000	Greff et al.	6,527,863 B1	3/2003	Pacetti et al.
6,033,582 A	3/2000	Lee et al.	6,528,526 B1	3/2003	Myers et al.
6,034,204 A	3/2000	Mohr et al.	6,530,950 B1	3/2003	Alvarado et al.
6,042,875 A	3/2000	Ding et al.	6,530,951 B1	3/2003	Bates et al.
6,051,576 A	4/2000	Ashton et al.	6,540,776 B2	4/2003	Sanders Millare et al.
6,051,648 A	4/2000	Rhee et al.	6,544,223 B1	4/2003	Kokish
6,054,553 A	4/2000	Groth et al.	6,544,543 B1	4/2003	Mandrusov et al.
6,056,993 A	5/2000	Leidner et al.	6,544,582 B1	4/2003	Yoe
6,060,451 A	5/2000	DiMaio et al.	6,555,157 B1	4/2003	Hossainy
6,060,518 A	5/2000	Kabanov et al.	6,558,733 B1	5/2003	Hossainy et al.
6,080,488 A	6/2000	Hostettler et al.	6,565,659 B1	5/2003	Pacetti et al.
6,096,070 A	8/2000	Ragheb et al.	6,572,644 B1	6/2003	Moein
6,099,562 A	8/2000	Ding et al.	6,585,755 B2	7/2003	Jackson et al.
6,099,563 A	8/2000	Zhong	6,585,765 B1	7/2003	Hossainy et al.
6,110,188 A	8/2000	Narciso, Jr.	6,585,926 B1	7/2003	Mirzaee
6,110,483 A	8/2000	Whitbourne et al.	6,589,597 B1 *	7/2003	Ono et al. 427/195
6,113,629 A	9/2000	Ken	6,605,154 B1	8/2003	Villareal
6,120,491 A	9/2000	Kohn et al.	6,616,765 B1	9/2003	Hossainy et al.
6,120,536 A	9/2000	Ding et al.	6,623,448 B2	9/2003	Slater
			6,625,486 B2	9/2003	Lundkvist et al.
			6,645,135 B1	11/2003	Bhat
			6,645,195 B1	11/2003	Bhat et al.
			6,656,216 B1	12/2003	Hossainy et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,656,506 B1 12/2003 Wu et al.
 6,660,034 B1 12/2003 Mandrusov et al.
 6,663,662 B2 12/2003 Pacetti et al.
 6,663,880 B1 12/2003 Roorda et al.
 6,666,880 B1 12/2003 Chiu et al.
 6,673,154 B1 1/2004 Pacetti et al.
 6,673,385 B1 1/2004 Ding et al.
 6,689,099 B2 2/2004 Mirzaee
 6,695,920 B1 2/2004 Pacetti et al.
 6,706,013 B1 3/2004 Bhat et al.
 6,709,514 B1 3/2004 Hossainy
 6,712,845 B2 3/2004 Hossainy
 6,713,119 B2 3/2004 Hossainy et al.
 6,716,444 B1 4/2004 Castro et al.
 6,723,120 B2 4/2004 Yan
 6,733,768 B2 5/2004 Hossainy et al.
 6,740,040 B1 5/2004 Mandrusov et al.
 6,743,462 B1 6/2004 Pacetti
 6,749,626 B1 6/2004 Bhat et al.
 6,753,071 B1 6/2004 Pacetti
 6,758,859 B1 7/2004 Dang et al.
 6,759,054 B2 7/2004 Chen et al.
 6,764,505 B1 7/2004 Hossainy et al.
 6,808,533 B1 10/2004 Goodwin et al.
 6,833,004 B2 12/2004 Ishii et al.
 6,861,088 B2 3/2005 Weber et al.
 6,865,810 B2 3/2005 Stinson
 6,869,443 B2 3/2005 Buscemi et al.
 6,878,160 B2 4/2005 Gilligan et al.
 6,887,270 B2 5/2005 Miller et al.
 6,887,485 B2 5/2005 Fitzhugh et al.
 6,890,546 B2 5/2005 Mollison et al.
 6,899,731 B2 5/2005 Li et al.
 6,926,919 B1 * 8/2005 Hossainy et al. 427/2.25
 7,063,884 B2 6/2006 Hossainy et al.
 7,192,638 B2 * 3/2007 Tomihashi et al. 428/327
 7,261,946 B2 * 8/2007 Claude 428/500
 2001/0007083 A1 7/2001 Roorda
 2001/0014717 A1 8/2001 Hossainy et al.
 2001/0018469 A1 8/2001 Chen et al.
 2001/0020011 A1 9/2001 Mathiowitz et al.
 2001/0029351 A1 10/2001 Falotico et al.
 2001/0037007 A1 11/2001 Lousenberg et al.
 2001/0037145 A1 11/2001 Guruwaiya et al.
 2001/0051608 A1 12/2001 Mathiowitz et al.
 2002/0005206 A1 1/2002 Falotico et al.
 2002/0007213 A1 1/2002 Falotico et al.
 2002/0007214 A1 1/2002 Falotico
 2002/0007215 A1 1/2002 Falotico et al.
 2002/0009604 A1 1/2002 Zamora et al.
 2002/0016625 A1 2/2002 Falotico et al.
 2002/0032414 A1 3/2002 Ragheb et al.
 2002/0032434 A1 3/2002 Chudzik et al.
 2002/0040119 A1 4/2002 Tang et al.
 2002/0051730 A1 5/2002 Bodnar et al.
 2002/0071822 A1 6/2002 Urich
 2002/0077693 A1 6/2002 Barclay et al.
 2002/0082679 A1 6/2002 Sirhan et al.
 2002/0087123 A1 7/2002 Hossainy et al.
 2002/0091433 A1 7/2002 Ding et al.
 2002/0094440 A1 7/2002 Llanos et al.
 2002/0111590 A1 8/2002 Davila et al.
 2002/0120326 A1 8/2002 Michal
 2002/0123801 A1 9/2002 Pacetti et al.
 2002/0142039 A1 10/2002 Claude
 2002/0155212 A1 10/2002 Hossainy
 2002/0165608 A1 11/2002 Llanos et al.
 2002/0176849 A1 11/2002 Slepian
 2002/0183581 A1 12/2002 Yoe et al.
 2002/0188037 A1 12/2002 Chudzik et al.
 2002/0188277 A1 12/2002 Roorda et al.
 2003/0004141 A1 1/2003 Brown
 2003/0028243 A1 2/2003 Bates et al.
 2003/0028244 A1 2/2003 Bates et al.
 2003/0031780 A1 2/2003 Chudzik et al.

2003/0032767 A1 2/2003 Tada et al.
 2003/0036794 A1 2/2003 Ragheb et al.
 2003/0039689 A1 2/2003 Chen et al.
 2003/0040712 A1 2/2003 Ray et al.
 2003/0040790 A1 2/2003 Furst
 2003/0059520 A1 3/2003 Chen et al.
 2003/0060877 A1 3/2003 Falotico et al.
 2003/0065377 A1 4/2003 Davila et al.
 2003/0072868 A1 4/2003 Harish et al.
 2003/0073961 A1 4/2003 Happ
 2003/0083646 A1 5/2003 Sirhan et al.
 2003/0083739 A1 5/2003 Cafferata
 2003/0097088 A1 5/2003 Pacetti
 2003/0097173 A1 5/2003 Dutta
 2003/0099712 A1 5/2003 Jayaraman
 2003/0105518 A1 6/2003 Dutta
 2003/0113439 A1 6/2003 Pacetti et al.
 2003/0130455 A1 * 7/2003 Patil et al. 526/219.6
 2003/0150380 A1 8/2003 Yoe
 2003/0157241 A1 8/2003 Hossainy et al.
 2003/0158517 A1 8/2003 Kokish
 2003/0190406 A1 10/2003 Hossainy et al.
 2003/0207020 A1 11/2003 Villareal
 2003/0211230 A1 11/2003 Pacetti et al.
 2004/0018296 A1 1/2004 Castro et al.
 2004/0029952 A1 2/2004 Chen et al.
 2004/0047978 A1 3/2004 Hossainy et al.
 2004/0047980 A1 3/2004 Pacetti et al.
 2004/0052858 A1 3/2004 Wu et al.
 2004/0052859 A1 3/2004 Wu et al.
 2004/0054104 A1 3/2004 Pacetti
 2004/0060508 A1 4/2004 Pacetti et al.
 2004/0062853 A1 4/2004 Pacetti et al.
 2004/0063805 A1 4/2004 Pacetti et al.
 2004/0071861 A1 4/2004 Mandrusov et al.
 2004/0072922 A1 4/2004 Hossainy et al.
 2004/0073298 A1 4/2004 Hossainy
 2004/0086542 A1 5/2004 Hossainy et al.
 2004/0086550 A1 5/2004 Roorda et al.
 2004/0096504 A1 5/2004 Michal
 2004/0098117 A1 5/2004 Hossainy et al.
 2007/0003588 A1 * 1/2007 Chinn et al. 424/423
 2007/0228617 A1 * 10/2007 Higashi et al. 264/446

FOREIGN PATENT DOCUMENTS

EP 0 161804 4/1985
 EP 0 301 856 2/1989
 EP 0 396 429 11/1990
 EP 0 514 406 11/1992
 EP 0 369 727 2/1994
 EP 0 604 022 6/1994
 EP 0 623 354 11/1994
 EP 0 665 023 8/1995
 EP 0 701 802 3/1996
 EP 0 716 836 6/1996
 EP 0 809 999 12/1997
 EP 0 832 655 4/1998
 EP 0 850 651 7/1998
 EP 0 879 595 11/1998
 EP 0 910 584 4/1999
 EP 0 923 953 6/1999
 EP 0 953 320 11/1999
 EP 0 970 711 1/2000
 EP 0 982 041 3/2000
 EP 1 023 879 8/2000
 EP 1 192 957 4/2002
 EP 1 273 314 1/2003
 GB 1 089 147 11/1967
 GB 1 092 739 11/1967
 JP 60-221410 11/1985
 JP 60-251041 12/1985
 JP 01-245007 9/1989
 JP 02-182710 7/1990
 JP 08-506140 7/1996
 JP 11-506944 6/1999
 JP 2001-190687 7/2001
 JP 2002-345972 12/2002
 JP 2003-093520 4/2003

(56)

References Cited

FOREIGN PATENT DOCUMENTS

JP	2004-510850	4/2004
SU	872531	10/1981
SU	876663	10/1981
SU	905228	2/1982
SU	790725	2/1983
SU	1016314	5/1983
SU	811750	9/1983
SU	1293518	2/1987
WO	WO 90/15828	12/1990
WO	WO 91/12846	9/1991
WO	WO 94/02185	2/1994
WO	WO 94/09760	5/1994
WO	WO 94/18248	8/1994
WO	WO 95/10989	4/1995
WO	WO 95/24929	9/1995
WO	WO 96/35577	11/1996
WO	WO 96/40174	12/1996
WO	WO 97/10011	3/1997
WO	WO 97/45105	12/1997
WO	WO 97/46590	12/1997
WO	WO 98/08463	3/1998
WO	WO 98/17331	4/1998
WO	WO 98/32398	7/1998
WO	WO 98/36784	8/1998
WO	WO 99/01118	1/1999
WO	WO 99/38546	8/1999
WO	WO 99/63981	12/1999
WO	WO 00/02599	1/2000
WO	WO 00/12147	3/2000
WO	WO 00/18446	4/2000
WO	WO 00/64506	11/2000
WO	WO 01/01890	1/2001
WO	WO 01/15751	3/2001
WO	WO 01/17577	3/2001
WO	WO 01/45763	6/2001
WO	WO 01/49338	7/2001
WO	WO 01/51027	7/2001
WO	WO 01/74414	10/2001
WO	WO 02/03890	1/2002
WO	WO 02/26162	4/2002
WO	WO 02/28925	4/2002
WO	WO 02/34311	5/2002
WO	WO 02/056790	7/2002
WO	WO 02/058753	8/2002
WO	WO 02/102283	12/2002
WO	WO 03/000308	1/2003
WO	WO 03/022323	3/2003
WO	WO 03/028780	4/2003
WO	WO 03/037223	5/2003
WO	WO 03/039612	5/2003
WO	WO 03/080147	10/2003
WO	WO 03/082368	10/2003
WO	WO 2004/000383	12/2003
WO	WO 2004/009145	1/2004
WO	WO 2004/101018	11/2004

OTHER PUBLICATIONS

Search Report for PCT/US2005/045982 filed Dec. 16, 2005, mailed Nov. 7, 2006, 13 pgs.

Anonymous, *Cardiologists Draw—Up The Dream Stent*, Clinica 710:15 (Jun. 17, 1996), <http://www.dialogweb.com/cgi/document?req=1061848202959>, printed Aug. 25, 2003 (2 pages).

Anonymous, *Heparin-coated stents cut complications by 30%*, Clinica 732:17 (Nov. 18, 1996), <http://www.dialogweb.com/cgi/document?req=1061847871753>, printed Aug. 25, 2003 (2 pages).

Anonymous, *Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent* (Abstract 434009), Res. Disclos. pp. 974-975 (Jun. 2000).

Anonymous, *Stenting continues to dominate cardiology*, Clinica 720:22 (Sep. 2, 1996), <http://www.dialogweb.com/cgi/document?req=1061848017752>, printed Aug. 25, 2003 (2 pages).

Aoyagi et al., *Preparation of cross-linked aliphatic polyester and application to thermo-responsive material*, Journal of Controlled Release 32:87-96 (1994).

Barath et al., *Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury*, JACC 13(2): 252A (Abstract) (Feb. 1989).

Barbucci et al., *Coating of commercially available materials with a new heparinizable material*, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).

Chung et al., *Inner core segment design for drug delivery control of thermo-responsive polymeric micelles*, Journal of Controlled Release 65:93-103 (2000).

Dev et al., *Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs*, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).

Dichek et al., *Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells*, Circ. 80(5):1347-1353 (Nov. 1989).

Eigler et al., *Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin*, JACC, 4A (701-1), Abstract (Feb. 1994).

Helmus, *Overview of Biomedical Materials*, MRS Bulletin, pp. 33-38 (Sep. 1991).

Herdeg et al., *Antiproliferative Stent Coatings: Taxol and Related Compounds*, Semin. Intervent. Cardiol. 3:197-199 (1998).

Huang et al., *Biodegradable Polymers Derived from Aminoacids*, Macromol. Symp. 144, 7-32 (1999).

Inoue et al., *An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs*, Journal of Controlled Release 51:221-229 (1998).

Kataoka et al., *Block copolymer micelles as vehicles for drug delivery*, Journal of Controlled Release 24:119-132 (1993).

Katsarava et al., *Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α -amino acid) α,ω -Alkylene Diesters, and Aliphatic Dicarboxylic Acids*, Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).

Levy et al., *Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants*, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).

Liu et al., *Drug release characteristics of unimolecular polymeric micelles*, Journal of Controlled Release 68:167-174 (2000).

Marconi et al., *Covalent bonding of heparin to a vinyl copolymer for biomedical applications*, Biomaterials 18(12):885-890 (1997).

Matsumaru et al., *Emboloc Materials for Endovascular Treatment of Cerebral Lesions*, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).

Miyazaki et al., *Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice*, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).

Miyazawa et al., *Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat*, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).

Nordrehaug et al., *A novel biocompatible coating applied to coronary stents*, EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).

Ohsawa et al., *Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty*, American Heart Journal 136(6):1081-1087 (Dec. 1998).

Ozaki et al., *New Stent Technologies*, Progress in Cardiovascular Diseases, vol. XXXIX(2):129-140 (Sep./Oct. 1996).

Pechar et al., *Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin*, Bioconjugate Chemistry 11(2):131-139 (Mar./Apr. 2000).

Peng et al., *Role of polymers in improving the results of stenting in coronary arteries*, Biomaterials 17:685-694 (1996).

Saotome, et al., *Novel Enzymatically Degradable Polymers Comprising α -Amino Acid, 1,2-Ethanediol, and Adipic Acid*, Chemistry Letters, pp. 21-24, (1991).

Shigeno, *Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor*, Chemical Abstract 125:212307 (1996).

(56)

References Cited

OTHER PUBLICATIONS

van Beusekom et al., *Coronary stent coatings*, *Coronary Artery Disease* 5(7):590-596 (Jul. 1994).

Wilensky et al., *Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries*, *Trends Cardiovasc. Med.* 3(5):163-170 (1993).

Yokoyama et al., *Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their*

design for in vivo delivery to a solid tumor, *Journal of Controlled Release* 50:79-92 (1998).

Translation of Notice of Reasons for Rejection for appl. No. JP 2007-548361, mailed Dec. 6, 2011, 3 pgs.

Kopecek et al. *Prog. Polym. Sci* vol. 9, p. 34, (1983).

Zhang et al., "Synthesis of fluorine-containing block copolymers via ATRP 1. Synthesis and characterization of PSt-PVDF-PSt triblock copolymers", *Polymer* 40, pp. 1341-1345 (1999).

* cited by examiner

**POLYMERS OF FLUORINATED MONOMERS
AND HYDROCARBON MONOMERS**

CROSS REFERENCE

This is a divisional application of application Ser. No. 11/021,775 filed on Dec. 22, 2004, the teachings of which are incorporated herein in their entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention generally relates to a polymeric material useful for coating an implantable device, such as a stent.

2. Description of the Background

Although stents work well mechanically, the chronic issues of restenosis and, to a lesser extent, stent thrombosis remain. Pharmacological therapy in the form of a drug-delivery stent appears a feasible means to tackle these biologically derived issues. Polymeric coatings placed onto the stent serve to act both as the drug reservoir, and to control the release of the drug. One of the commercially available polymer coated products is a stent manufactured by Boston Scientific. For example, U.S. Pat. Nos. 5,869,127; 6,099,563; 6,179,817; and 6,197,051, assigned to Boston Scientific Corporation, describe various compositions for coating medical devices. These compositions provide to stents described therein an enhanced biocompatibility and may optionally include a bioactive agent. U.S. Pat. No. 6,231,590 to Scimed Life Systems, Inc., describes a coating composition, which includes a bioactive agent, a collagenous material, or a collagenous coating optionally containing or coated with other bioactive agents.

The nature of the coating polymers plays an important role in defining the surface properties of a coating. For example, a very low T_g , amorphous coating material induces unacceptable rheological behavior upon mechanical perturbation such as crimping, balloon expansion, etc. On the other hand, a high T_g , or highly crystalline coating material introduces brittle fracture in the high strain areas of the stent pattern. Furthermore, a very low T_g , amorphous coating material can have a high drug permeability leading to an unacceptably high drug release rate. While a high T_g , or highly crystalline coating material can have a very low polymer permeability, which lead to an unacceptably low drug release rate. These are general principles which must also be combined with the properties of the drug such as the drug solubility in the polymer and in the tissue.


Some of the currently used polymeric materials have some undesirable properties such as lack of sufficient elongation to use on a stent or low permeability to drugs. One such polymer is poly(vinylidene fluoride) (PVDF). Therefore, there is a need for new polymeric materials suitable for use as coating materials on implantable devices.

The present invention addresses such problems by providing a polymeric material for coating implantable devices.

SUMMARY OF THE INVENTION

Provided herein is a polymer containing fluorinated monomers and hydrocarbon monomers useful for coating an implantable device such as a stent. The fluorinated monomers can provide mechanical strength for the polymer. The hydrocarbon monomers described herein impart flexibility to the polymer.

In one embodiment, the polymer can be a random or block polymer having a general formula as shown below (Formula I):



where m and n can be positive integers ranging from 1 to 100,000.

The fluoro monomers are generally fluorinated alkylene monomers and can be unsubstituted or substituted fluorinated ethylene. In one embodiment, the fluoro monomer is a substituted fluorinated ethylene bearing a substituent (R) such as $\text{---CF}_2\text{---CRF---}$, ---CHF---CRF--- , $\text{---CH}_2\text{---CRF---}$, $\text{---CF}_2\text{---CRH---}$, and ---CFH---CRH--- . R can be hydrogen, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, short chain alkyl groups, phenyl, substituted phenyl, cyclic alkyl, heterocyclic, heteroaryl, fluorinated short chain alkyl groups, fluorinated phenyl, fluorinated cyclic alkyl, fluorinated heterocyclic, or combinations thereof. Some exemplary fluorinated alkylene monomers include tetrafluoroethylene, trifluoroethylene, vinylidene fluoride, chlorotrifluoroethylene, pentafluoropropene, hexafluoropropene, vinyl fluoride, and ---CHF---CHF--- .

The hydrocarbon monomers can be any hydrocarbon vinyl monomers or substituted hydrocarbon vinyl monomers capable of forming biocompatible polymers. The hydrocarbon vinyl monomers generally have the formulae CHR=CH_2 or $\text{CR}_2=\text{CH}_2$ in which R can be hydrogen, methyl, ethyl, n-propyl, isopropyl, short chain alkyl groups, phenyl, substituted phenyl, cyclic alkyl, heterocyclic, heteroaryl, or combinations thereof. Representative hydrocarbon vinyl monomers include isobutylene, styrene, methyl styrene, and alkyl substituted styrene. Other hydrocarbon monomers that will yield biocompatible polymers include, but are not limited to, ethylene, propylene, and butylene.

In another embodiment, the hydrocarbon monomer can be a non vinyl monomer. Useful non vinyl monomers include CHR=CHR or $\text{CR}_2=\text{CHR}$ in which R can be methyl, ethyl, n-propyl, isopropyl, short chain alkyl groups, phenyl, substituted phenyl, cyclic alkyl, heterocyclic, heteroaryl, or combinations thereof. Representative non vinyl monomers include, but are not limited to, 2-butylene, 2-pentene, 2-hexene, and 3-hexene.

In the polymer of Formula I, the fluoro monomers generally account for about 25.01 mole % to about 99.99 mole %, or more narrowly, 50.01 mole % to about 94.99% of the total monomers forming the polymer, and the hydrocarbon monomers generally account for about 0.01 mole % to about 74.99 mole % mole %, or more narrowly 5.01 mole % to about 49.99 mole % of the total monomers forming the polymer. By varying the mole percentages of the two components of the polymer, one can fine-tune physical properties of the polymer. The polymer described herein can be a random or block copolymer.

In another embodiment, it is provided a polymer blend that includes a polymer that has fluorinated monomers and at least one other biocompatible polymer. In one embodiment, the polymer that has fluorinated monomers has a structure of Formula I as defined above.

The polymer or polymer blends described herein, optionally with a bioactive agent, can be used to form an implantable device such as a stent or coating(s) on an implantable device such as a stent. Some exemplary bioactive agents are paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide


dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-o-(2-hydroxy)ethyl-rapamycin (everolimus), 40-o-(3-hydroxy)propyl-rapamycin, 40-o-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-o-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and combinations thereof. The implantable device can be implanted in a patient to treat, prevent or ameliorate a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

DETAILED DESCRIPTION

Provided herein is a polymer containing fluorinated monomers and hydrocarbon monomers. The fluorinated monomers can provide mechanical strength for the polymer. The hydrocarbon monomers impart flexibility to the polymer. The polymer or polymer blends described herein, optionally with a bioactive agent, can be used to form an implantable device such as a stent or coating(s) on an implantable device such as a stent. Some exemplary bioactive agents are paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-o-(2-hydroxy)ethyl-rapamycin (everolimus), 40-o-(3-hydroxy)propyl-rapamycin, 40-o-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-o-tetrazole-rapamycin, ABT-578, clobetasol, prodrugs thereof, co-drugs thereof, and combinations thereof. The implantable device can be implanted in a patient to treat, prevent or ameliorate a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

Polymers of Fluorinated Monomers and Hydrophilic Monomers

In one embodiment, the polymer can be a random or block polymer having a general formula as shown below (Formula I):



where m and n can be positive integers ranging from, e.g., 1 to 100,000.


The fluoro monomers are generally fluorinated alkylene monomers and can be unsubstituted or substituted fluorinated ethylene. In one embodiment, the fluoro monomer is a substituted fluorinated ethylene bearing a substituent (R) such as $\text{---CF}_2\text{---CRF---}$, ---CHF---CRF--- , $\text{---CH}_2\text{---CRF---}$, $\text{---CF}_2\text{---CRH---}$, and ---CFH---CRH--- . R can be hydrogen, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, short chain alkyl groups, phenyl, substituted phenyl, cyclic alkyl, heterocyclic, heteroaryl, fluorinated short chain alkyl groups, fluorinated phenyl, fluorinated cyclic alkyl, fluorinated heterocyclic, or combinations thereof. Some exemplary fluorinated alkylene

monomers include tetrafluoroethylene, trifluoroethylene, vinylidene fluoride, chlorotrifluoroethylene, pentafluoropropene, hexafluoropropene, vinyl fluoride, and ---CHF---CHF--- .

The hydrocarbon monomers can be any hydrocarbon vinyl monomers or substituted hydrocarbon vinyl monomers capable of forming biocompatible polymers. The hydrocarbon vinyl monomers generally have the formulas CHR=CH_2 or $\text{CR}_2\text{=CH}_2$ in which R can be hydrogen, methyl, ethyl, n-propyl, isopropyl, short chain alkyl groups, phenyl, substituted phenyl, cyclic alkyl, heterocyclic, heteroaryl, or combinations thereof. Representative hydrocarbon vinyl monomers include isobutylene, styrene, methyl styrene, and alkyl substituted styrene. Other hydrocarbon monomers that will yield biocompatible polymers include, but are not limited to, ethylene, propylene, butylene.

In the polymer of Formula I, the fluoro monomers generally account for about 25.01 mole % to about 99.99 mole %, or more narrowly, 50.01 mole % to about 94.99% of the total repeating units forming the polymer, and the hydrocarbon monomers generally account for about 0.01 mole % to about 74.99 mole % mole %, or more narrowly 5.01 mole % to about 49.99 mole % of the total repeating units forming the polymer. By varying the mole percentages of the two components of the polymer, one can fine-tune physical properties of the polymer. The polymer described herein can be a random or block copolymer.

In one embodiment, the polymer of formula I has a structure of formula II or formula III:



Formula II

Formula III

The polymer described herein can be synthesized by methods known in the art (see, for example, D. Braun, et al., Polymer Synthesis: Theory and Practice. Fundamentals, Methods, Experiments. 3rd Ed., Springer, 2001; Hans R. Kricheldorf, Handbook of Polymer Synthesis, Marcel Dekker Inc., 1992). For example, one method that can be used to make the polymer can be free radical methods (see, for example, D. Braun, et al., Polymer Synthesis: Theory and Practice. Fundamentals, Methods, Experiments. 3rd Ed., Springer, 2001; Hans R. Kricheldorf, Handbook of Polymer Synthesis, Marcel Dekker Inc., 1992). Polymerization in solvent can also be used to synthesize the polymer described herein.

Copolymerization prevents phase separation on a large scale. For systems where the reactivity ratios greatly differ, a random polymerization will result in more and more of a block structure. Otherwise, polymerizations that proceed step-wise via the formation of prepolymers may be used to achieve block structures (See, for example, J. Kopecek, et al., Prog. Polym. Sci, 9:34 (1983)).

Polymer Blends

In another embodiment, the polymer of formulae I-III can be blended with another biocompatible polymer to form a coating material for an implantable device. The biocompatible polymer can be biodegradable or nondegradable. Representative examples of these biocompatible polymers include, but are not limited to, poly(ester amide), polyesters, polyhydroxyalkanoates (PHA), poly(3-hydroxyalkanoates) such as poly(3-hydroxypropanoate), poly(3-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(3-hydroxyheptanoate) and poly(3-hydroxyoctanoate), poly(4-hydroxyalkanoates) such as poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), poly(4-hydroxyheptanoate), poly(4-hydroxyoctanoate) and copolymers including any of the 3-hydroxyalkanoate or 4-hydroxyalkanoate monomers described herein or blends thereof, poly(D,L-lactide), poly(L-lactide), polyglycolide, poly(D,L-lactide-co-glycolide), poly(L-lactide-co-glycolide), polycaprolactone, poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(dioxanone), poly(ortho esters), poly(anhydrides), poly(tyrosine carbonates) and derivatives thereof, poly(tyrosine ester) and derivatives thereof, poly(imino carbonates), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyurethanes, polyphosphazenes, silicones, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, poly(methylmethacrylate), poly(ethyl methacrylate), poly(isopropyl methacrylate), poly(n-propyl methacrylate), poly(n-butyl methacrylate), methacrylic polymers and copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride, poly(vinylidene fluoride), poly(vinylidene fluoride-co-hexafluoropropylene), polyvinyl ethers such as polyvinyl methyl ether, polyvinylidene halides such as polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics such as polystyrene, polyvinyl esters such as polyvinyl acetate, copolymers of vinyl monomers with each other and olefins such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers, polyamides such as Nylon 66 and polycaprolactam, alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, poly(glyceryl sebacate), poly(propylene fumarate), epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, carboxymethyl cellulose, polyethers such as poly(ethylene glycol) (PEG), copoly(ether-esters), e.g., copoly(ethylene oxide-co-lactic acid) (PEO/PLA), polyalkylene oxides such as poly(ethylene oxide) and poly(propylene oxide), polyalkylene oxalates, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, PEG acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxy methacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONICTM sur-

factants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), biomolecules such as collagen, chitosan, alginate, fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosaminoglycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, and combinations thereof. In some embodiments, the polymer can exclude any one of the aforementioned polymers.

As used herein, the terms poly(D,L-lactide) (PDLL), poly(L-lactide) (PLL), poly(D,L-lactide-co-glycolide) (PDLLG), and poly(L-lactide-co-glycolide) (PLLG) are used interchangeably with the terms poly(D,L-lactic acid) (PDLLA), poly(L-lactic acid) (PLLA), poly(D,L-lactic acid-co-glycolic acid) (PDLLAGA), and poly(L-lactic acid-co-glycolic acid) (PLLAGA), respectively.

Bioactive Agents

In accordance with a further embodiment of the invention, the polymer or polymer blend described herein can form a coating that may optionally include one or more active agents. The bioactive agent can be any agent that is biologically active, for example, a therapeutic, prophylactic, or diagnostic agent.

Examples of suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes. Compounds with a wide range of molecular weight can be encapsulated, for example, between 100 and 500,000 grams or more per mole. Examples of suitable materials include proteins such as antibodies, receptor ligands, and enzymes, peptides such as adhesion peptides, saccharides and polysaccharides, synthetic organic or inorganic drugs, and nucleic acids. Examples of materials which can be encapsulated include enzymes, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, polysaccharides such as heparin, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. The polymer can also be used to encapsulate cells and tissues. Representative diagnostic agents are agents detectable by x-ray, fluorescence, magnetic resonance imaging, radioactivity, ultrasound, computer tomography (CT) and positron emission tomography (PET). Ultrasound diagnostic agents are typically a gas such as air, oxygen or perfluorocarbons.

In the case of controlled release, a wide range of different bioactive agents can be incorporated into a controlled release device. These include hydrophobic, hydrophilic, and high molecular weight macromolecules such as proteins. The bioactive compound can be incorporated into polymeric coating in a percent loading of between 0.01% and 70% by weight, more preferably between 5% and 50% by weight.

In one embodiment, the bioactive agent can be for inhibiting the activity of vascular smooth muscle cells. More specifically, the bioactive agent can be aimed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells for the inhibition of restenosis. The bioactive agent can also include any substance capable of exerting a therapeutic or prophylactic effect in the practice of the present invention. For example, the bioactive agent can be for enhanc-

ing wound healing in a vascular site or improving the structural and elastic properties of the vascular site. Examples of active agents include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, Wis. 53233, or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I₁, actinomycin X₁, and actinomycin C₁. The bioactive agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel, (e.g. TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. Taxotere®, from Aventis S.A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapirost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as Angiomax a (Biogen, Inc., Cambridge, Mass.). Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.), calcium channel blockers (such as nifedipine), colchicine, proteins, peptides, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thio-protease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate agents include alpha-interferon, genetically engineered epithelial cells, anti-inflammatory agents, steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, antivirals, anticancer drugs, anticoagulant agents, free radical scavengers, estradiol, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-o-(2-hydroxy)ethyl-rapamycin (everolimus), 40-o-(3-hydroxy)propyl-rapamycin, 40-o-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-o-tetrazole-rapamycin, ABT-578, clobetasol, cytostatic agents, prodrugs thereof, co-drugs thereof, or a combination thereof.

The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents which are currently available or that may be developed in the future are equally applicable.

The dosage or concentration of the bioactive agent required to produce a favorable therapeutic effect should be less than the level at which the bioactive agent produces toxic effects and greater than the level at which non-therapeutic results are obtained. The dosage or concentration of the bioactive agent

required to inhibit the desired cellular activity of the vascular region can depend upon factors such as the particular circumstances of the patient; the nature of the trauma; the nature of the therapy desired; the time over which the ingredient administered resides at the vascular site; and if other active agents are employed, the nature and type of the substance or combination of substances. Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.

Examples of Implantable Device

As used herein, an implantable device may be any suitable medical substrate that can be implanted in a human or veterinary patient. Examples of such implantable devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, closure devices for patent foramen ovale, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, Calif.). The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N," "MP20N," ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. "MP35N" and "MP20N" are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, Pa. "MP35N" consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. "MP20N" consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention.

Method of Use

In accordance with embodiments of the invention, a coating of the various described embodiments can be formed on an implantable device or prosthesis, e.g., a stent. For coatings including one or more active agents, the agent will retain on the medical device such as a stent during delivery and expansion of the device, and released at a desired rate, and for a predetermined duration of time at the site of implantation. Preferably, the medical device is a stent. A stent having the above-described coating is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways. A stent having the above-described coating is particularly useful for treating occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, atherosclerosis, thrombosis, and restenosis. Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, carotid, and coronary arteries.

For implantation of a stent, an angiogram is first performed to determine the appropriate positioning for stent therapy. An angiogram is typically accomplished by injecting a radiopaque contrasting agent through a catheter inserted into an

artery or vein as an x-ray is taken. A guidewire is then advanced through the lesion or proposed site of treatment. Over the guidewire is passed a delivery catheter, which allows a stent in its collapsed configuration to be inserted into the passageway. The delivery catheter is inserted either percutaneously, or by surgery, into the femoral artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance. A stent having the above-described coating may then be expanded at the desired area of treatment. A post-insertion angiogram may also be utilized to confirm appropriate positioning.

EXAMPLES

The embodiments of the present invention will be illustrated by the following set forth prophetic examples. All parameters and data are not to be construed to unduly limit the scope of the embodiments of the invention.

Example 1

Synthesis of poly(block-vinylidene fluoride-co-block-isobutylene)

Fluoropolymers are typically synthesized by free radical polymerization, using suspension or emulsion techniques, while polyisobutylene is typically produced via cationic polymerization methods (see G. Odian, Principles of Polymerization, 3rd Ed., John Wiley & Sons, NY, 1991). However, fluoropolymers can also be synthesized by atom transfer radical polymerization (ATRP) using iodine or bromine functional initiators. These polymerizations result in PVDF with terminal iodine or bromine groups. These endgroups can then be used directly, or functionalized, to serve as carbocationic initiators for isobutylene. A block co-polymer can be made by first synthesizing a bromo-terminated poly(vinylidene fluoride) via ATRP techniques (see Z. Zhang, et al. "Synthesis of fluorine-containing block copolymers via ATRP 1. Synthesis and characterization of PSt-PVDF-PSt triblock copolymers", Polymer (40) (1999) 1341-1345). The resulting bromo-terminated PVDF can then be used as an initiator in a cationic polymerization catalyzed by a lewis acid such as titanium tetrachloride, titanium tetrabromide, or aluminum trichloride (see J. P. Kennedy, et al. "Design Polymers by carbocationic Macromolecular Engineering", Hanser, N. Y., Munich, 1992). A useful weight ratio of vinylidene fluoride to isobutylene is 75/25.

Example 2

Synthesis of poly(vinylidene fluoride-co-styrene)

Both monomers are amenable to free radical polymerization. This polymerization can be via suspension or emulsion polymerization techniques. Useful initiators are peroxides, organic soluble peroxides, persulfate compounds, and azo compounds. Redox systems such as compounds containing ferrous, sulfite, or bisulfite ions can be used to produce desirable initiation rates at low temperatures. One useful route is suspension polymerization in an autoclave. A vinylidene fluoride/styrene copolymer dispersion can be prepared having a composition of 90% vinylidene fluoride and 10% styrene by weight. To a 10 gallon glass-lined autoclave is added 5 gallons of deionized water, and charged with 2.2 kg of vinylidene fluoride (VDF) and 0.24 kg of styrene. After sparging with nitrogen to remove all oxygen, and with rapid

stirring, a solution of 20 gm of a 70% solution of tertiary butyl hydroperoxide (TBHP) that is diluted to 100 ml with deionized water is added. Next, a solution of 15 gm of sodium metabisulfite (MBS), and 2.2 gm of ferrous sulfate heptahydrate, dissolved in 100 ml of deionized water is added. The autoclave is maintained at 15-20° C. After addition of the initial catalysts, 300 ml of perfluorinated ammonium octoate catalyst (20% active solids) is charged into the autoclave. The polymerization is continued by slow addition of two separate solutions consisting of 100 gm of TBHP diluted to 700 ml with deionized water and 80 gm of MBS diluted to 750 ml with deionized water. These initiators are added at a rate of 1.8 ml/min. After consumption of the initial charge of VDF and styrene, 18 kg of VDF and 2 kg of styrene are added over a period of 5 hours. The autoclave is vented, yielding a polymer dispersion in water which is isolated by sieving and rinsed.

Example 3

Coating a Stent with the Composition of Example 2

A composition can be prepared by mixing the following components:

- (a) about 2.0% (w/w) of poly(butyl methacrylate) (PBMA), and
- (b) the balance a 50/50 (w/w) blend of acetone and cyclohexanone. The composition can be applied onto the surface of bare 12 mm small VISION™ stent (Guidant Corp.). The coating can be sprayed and dried to form a primer layer. A spray coater can be used having a 0.014 round nozzle maintained at ambient temperature with a feed pressure 2.5 psi (0.17 atm) and an atomization pressure of about 15 psi (1.02 atm). About 20 µg of the coating can be applied at per one spray pass. About 80 µg of wet coating can be applied, and the stent can be dried for about 10 seconds in a flowing air stream at about 50° C. between the spray passes. The stents can be baked at about 80° C. for about one hour, yielding a drug reservoir layer composed of approximately 60 µg of PBMA. A second composition can be prepared by mixing the following components:

- (a) about 2.0% (w/w) of the polymer of example 2;
- (b) about 1.0% (w/w) of everolimus,
- (c) the balance a 50/50 (w/w) blend of acetone and dimethylformamide.


The second composition can be applied onto the dried primer layer to form a drug reservoir layer using the same spraying technique and equipment used for applying the reservoir. About 200 µg of wet coating can be applied followed by drying and baking at about 50° C. for about 2 hours, yielding a dry drug reservoir layer having solids content of about 180 µg and containing about 60 µg of everolimus.

While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

What is claimed is:

1. A biocompatible polymer comprising fluorinated monomers and hydrocarbon monomers, having the structure of formula I:

11



Formula I

wherein m and n are positive integers ranging from 1 to 100,000,

wherein the fluoro monomers are fluorinated alkylene monomers,

wherein the hydrocarbon monomers are hydrocarbon vinyl monomers,


wherein the hydrocarbon monomers are $\text{CR}_2=\text{CH}_2$ in which R is methyl, ethyl, n-propyl, isopropyl, short chain alkyl group, phenyl, substituted phenyl, cyclic alkyl, heterocyclic alkyl, or heteroaryl, or $\text{CHR}'=\text{CH}_2$ in which R' is phenyl, substituted phenyl, cyclic alkyl, heterocyclic alkyl, or heteroaryl,

wherein the fluoro monomers are selected from the group consisting of $-\text{CF}_2-\text{CF}_2-$, $-\text{CH}_2-\text{CHF}-$, $-\text{CHF}-\text{CHF}-$, $-\text{CClF}-\text{CF}_2-$, $-\text{CHF}-\text{C}(\text{CF}_3)\text{F}-$, $-\text{CF}_2-\text{C}(\text{CF}_3)\text{H}-$, $-\text{CF}_2-\text{CR}''\text{F}-$, $-\text{CHF}-\text{CR}''\text{F}-$, $-\text{CF}_2-\text{CR}''\text{H}-$, $-\text{CH}_2-\text{CR}''\text{F}-$, and $-\text{CFH}-\text{CR}''\text{H}-$ wherein R'' is selected from Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, short chain alkyl groups, substituted phenyl, cyclic alkyl, heterocyclic alkyl, heteroaryl, fluorinated short chain alkyl groups, fluorinated phenyl, fluorinated cyclic alkyl, and fluorinated heterocyclic groups,

wherein the fluorinated monomers form about 25.01 mole % to about 99.99 mole % repeating units of the polymer, and

wherein the hydrocarbon monomers form about 74.99 mole % to about 0.01 mole % repeating units of the polymer.

2. A biocompatible polymer comprising fluorinated monomers and hydrocarbon monomers, having the structure of formula I:



Formula I

wherein m and n are positive integers ranging from 1 to 100,000,

wherein the fluoro monomers are fluorinated alkylene monomers,

wherein the hydrocarbon monomers are hydrocarbon vinyl monomers,

12

wherein the hydrocarbon monomers are $\text{CR}_2=\text{CH}_2$ in which R is methyl, ethyl, n-propyl, isopropyl, short chain alkyl group, phenyl, substituted phenyl, cyclic alkyl, heterocyclic alkyl, or heteroaryl, or $\text{CHR}'=\text{CH}_2$ in which R' is phenyl, substituted phenyl, cyclic alkyl, heterocyclic alkyl, or heteroaryl,

wherein the fluoro monomers are selected from the group consisting of $-\text{CF}_2-\text{CF}_2-$, $-\text{CH}_2-\text{CHF}-$, $-\text{CHF}-\text{CHF}-$, $-\text{CClF}-\text{CF}_2-$, $-\text{CHF}-\text{C}(\text{CF}_3)\text{F}-$, $-\text{CF}_2-\text{C}(\text{CF}_3)\text{H}-$, $-\text{CF}_2-\text{CR}''\text{F}-$, $-\text{CHF}-\text{CR}''\text{F}-$, $-\text{CF}_2-\text{CR}''\text{H}-$, $-\text{CH}_2-\text{CR}''\text{F}-$, and $-\text{CFH}-\text{CR}''\text{H}-$ wherein R'' is selected from Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, short chain alkyl groups, substituted phenyl, cyclic alkyl, heterocyclic alkyl, heteroaryl, fluorinated short chain alkyl groups, fluorinated phenyl, fluorinated cyclic alkyl, and fluorinated heterocyclic groups,

wherein the fluorinated monomers form about 50.01 mole % to about 94.99 mole % units of the polymer, and

wherein the hydrocarbon monomers form about 49.99 mole % to about 5.01 mole % repeating units of the polymer.

3. The biocompatible polymer of claim 1, wherein the fluoro monomers are selected from the group consisting of $-\text{CH}_2-\text{CHF}-$, $-\text{CHF}-\text{CHF}-$, $-\text{CClF}-\text{CF}_2-$, $-\text{CHF}-\text{C}(\text{CF}_3)\text{F}-$, $-\text{CF}_2-\text{C}(\text{CF}_3)\text{H}-$, $-\text{CF}_2-\text{CR}''\text{F}-$, $-\text{CHF}-\text{CR}''\text{F}-$, $-\text{CF}_2-\text{CR}''\text{H}-$, $-\text{CH}_2-\text{CR}''\text{F}-$, and $-\text{CFH}-\text{CR}''\text{H}-$ wherein R'' is selected from Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, short chain alkyl groups, substituted phenyl, cyclic alkyl, heterocyclic alkyl, heteroaryl, fluorinated short chain alkyl groups, fluorinated phenyl, fluorinated cyclic alkyl, and fluorinated heterocyclic groups.

4. The biocompatible polymer of claim 2, wherein the fluoro monomers are selected from the group consisting of $-\text{CH}_2-\text{CHF}-$, $-\text{CHF}-\text{CHF}-$, $-\text{CClF}-\text{CF}_2-$, $-\text{CHF}-\text{C}(\text{CF}_3)\text{F}-$, $-\text{CF}_2-\text{C}(\text{CF}_3)\text{H}-$, $-\text{CF}_2-\text{CR}''\text{F}-$, $-\text{CHF}-\text{CR}''\text{F}-$, $-\text{CF}_2-\text{CR}''\text{H}-$, $-\text{CH}_2-\text{CR}''\text{F}-$, and $-\text{CFH}-\text{CR}''\text{H}-$ where R'' is selected from Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, short chain alkyl groups, substituted phenyl, cyclic alkyl, heterocyclic alkyl, heteroaryl, fluorinated short chain alkyl groups, fluorinated phenyl, fluorinated cyclic alkyl, and fluorinated heterocyclic groups.

5. The biocompatible polymer of claim 3 wherein the hydrocarbon monomer is one or more isobutylene, methyl styrene, or alkyl substituted styrene.

* * * * *